曲妥珠单抗联合SOX方案治疗HER-2阳性晚期胃癌的临床疗效观察  

Clinical Observation of Trastuzumab Combined with SOX Regimen in the Treatment of HER-2 Positive Advanced Gastric Cancer

作　　者：曹冉华[1] 苏乌云[1] 呼群[1] 刘彩霞[1] 赵海燕[1] 

机构地区：[1]内蒙古医科大学附属医院肿瘤内科,内蒙古呼和浩特010050

出　　处：《现代生物医学进展》2017年第4期680-683,共4页Progress in Modern Biomedicine

摘　　要：目的:探讨曲妥珠单抗联合替吉奥和奥沙利铂(SOX方案)治疗人类表皮生长因子受体-2(HER-2)阳性晚期胃癌的临床疗效。方法:选择2014年2月到2016年2月在我院收治的48例HER-2阳性晚期胃癌患者,随机分为实验组和对照组,各24例。对照组患者给予SOX化疗方案,实验组患者给予曲妥珠单抗联合SOX化疗方案,两组患者均给予治疗3个疗程。评价并比较两组患者临床疗效。比较两组患者治疗后不良反应发生情况。检测并比较两组患者治疗前后血清糖类抗原125(CA125)、癌胚抗原(CEA)及组织多肽特异性抗原(TPS)水平。结果:实验组患者的有效率(RR)为58.33%、疾病控制率(DCR)为87.50%,均明显高于对照组患者的29.17%和45.83%,差异具有统计学意义(P<0.05)。治疗后两组患者血清CA125、CEA及TPS水平均明显低于治疗前,且实验组患者上述各指标均明显低于对照组,差异具有统计学意义(P<0.05)。两组患者不良反应发生率比较差异均无统计学意义(P>0.05)。结论:曲妥珠单抗联合SOX方案治疗HER-2阳性晚期胃癌患者临床疗效显著,能够明显降低血清CA125、CEA及TPS水平,不良反应发生率低,值得在临床上推广应用。Objective： To study the clinical efficacy of trastuzumab combined with SOX regimen in the treatment of HER-2positive advanced gastric cancer. Methods： A total of 48 patients with HER2-positive advanced gastric cancer treated in our hospital from February 2014 to February 2016 were selected. They were divided into control group（n=24） and experiment group（n=24） randomly. The control group were treated with the SOX chemotherapy regimens, the experiment group were treated with trastuzumab combined with SOX chemotherapy regimens, the two groups were treated for 3 months. The clinical efficacy of the two groups were compared. The adverse reactions of the two groups were compared after treatment. The serum CA125, CEA and TPS level of the two groups were compared before and after treatment. Results： The RR of the experiment group was 58.33%, the DCR was 87.50%, which were significantly higher than 29.17% and 45.83% in the control group, the differences were statistically significant（P〈0.05）. The serum CA125,CEA and TPS level of the two groups after treatment were significantly lower than that before treatment（P〈0.05）, and that of experiment group were significantly lower than the control group, the differences were statistically significant（P〈0.05）. There were no significantly differences of the adverse effects rates in the two groups after treatment（P〉0.05）. Conclusion： The clinical efficacy of trastuzumab combined with SOX regimen in the treatment of advanced gastric cancer patients is significant, which can significantly reduce the serum CA125 CEA and TPS levels, the incidence of adverse reactions is low, so it is worthy clinical application.

关 键 词：曲妥珠单抗 替吉奥 奥沙利铂 胃癌 人类表皮生长因子受体-2 

分 类 号：R735.2[医药卫生—肿瘤]